This trial is testing a new cancer drug in patients with sarcoma, specifically those with myxoid liposarcoma or other sarcomas with similar chromosomal translocations to Ewing sarcoma. The trial will also test a combination of seclidemstat with topotecan and cyclophosphamide in patients with Ewing sarcoma.
1 Primary · 7 Secondary · Reporting Duration: From screening through at least 30 days after end of treatment, up to approximately 24 months
50 Total Participants · 3 Treatment Groups
Primary Treatment: Seclidemstat · No Placebo Group · Phase 1
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: